NICE launches new osteoporosis guidance

This month sees the launch of two new guidelines from NICE relating to the primary and secondary prevention of osteoporosis.

The first of the two new guidelines provides recommendations on the use of bisphosphonates, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women. For women who have been diagnosed with osteoporosis but have not yet had a fracture the bisphosphonate alendronate is recommended as a possible treatment, with risedronate and etidronate as alternatives if alendronate is contraindicated or not tolerated. If bisphosphonate treatment is unsuitable then strontium ranelate may be used as an alternative under certain circumstances.  The guidance states that raloxifene is not recommended as a treatment for preventing fractures in postmenopausal women who have not had a fracture.

In the second of the new guidelines NICE states that alendronate (or etidronate or risedronate) is recommended as a possible treatment for the secondary prevention of bone fractures in postmenopausal women with osteoporosis.  If bisphosphonates are unsuitable then strontium ranelate or raloxifene may be considered as possible alternatives under certain circumstances.  Teriparatide may be considered as an option for women who cannot take bisphosphonates or strontium ranelate or for women who have had another fracture after taking a bisphosphonate for one year (and whose bone density has fallen).

Summaries of the new guidance are available on www.mims.co.uk (Primary prevention, Secondary prevention)

 To read the full guidance visit the NICE website: Primary prevention, Secondary prevention.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases